TP53 and B-cell chronic lymphocytic leukemia: Although current international guidelines only recommend assessment of the mutational status of TP53 and IGHV prior to each line of treatment [5,6,7,8,9,10,14,16], during the last few years, high-throughput technology approaches have been developed and used in order to screen, simultaneously, a broad spectrum of CLL-related genes.